20/20 Biolabs（AIDX）株式概要20/20 Biolabs, Inc.は、がんや慢性疾患の早期発見と予防のために、AIを活用した検査室ベースの血液検査を開発・商品化している。 詳細AIDX ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長2/6過去の実績0/6財務の健全性5/6配当金0/6報酬収益は年間62.95%増加すると予測されています リスク分析キャッシュランウェイが1年未満である 今後3年間の収益は年平均26.5%減少すると予測されている。 US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $10M )+2 さらなるリスクすべてのリスクチェックを見るAIDX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.6048.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8m21m2016201920222025202620282031Revenue US$21.2mEarnings US$2.7mAdvancedSet Fair ValueView all narratives20/20 Biolabs, Inc. 競合他社Meihua International Medical TechnologiesSymbol: OTCPK:MHUA.FMarket cap: US$7.1mStandard Dental LabsSymbol: OTCPK:TUTHMarket cap: US$8.5mRetractable TechnologiesSymbol: NYSEAM:RVPMarket cap: US$20.9mRockwell MedicalSymbol: NasdaqCM:RMTIMarket cap: US$24.7m価格と性能株価の高値、安値、推移の概要20/20 Biolabs過去の株価現在の株価US$0.6052週高値US$50.0052週安値US$0.57ベータ01ヶ月の変化-55.54%3ヶ月変化-69.91%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-97.50%最新ニュースお知らせ • Jun 0220/20 Biolabs, Inc., Annual General Meeting, Aug 18, 202620/20 Biolabs, Inc., Annual General Meeting, Aug 18, 2026.お知らせ • May 1720/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).お知らせ • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.お知らせ • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.最新情報をもっと見るRecent updatesお知らせ • Jun 0220/20 Biolabs, Inc., Annual General Meeting, Aug 18, 202620/20 Biolabs, Inc., Annual General Meeting, Aug 18, 2026.お知らせ • May 1720/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).お知らせ • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.お知らせ • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.株主還元AIDXUS Medical EquipmentUS 市場7D-24.8%0.03%2.2%1Yn/a-20.4%24.8%株主還元を見る業界別リターン: AIDXがUS Medical Equipment業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: AIDX US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is AIDX's price volatile compared to industry and market?AIDX volatilityAIDX Average Weekly Movement17.9%Medical Equipment Industry Average Movement8.8%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.1%安定した株価: AIDXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のAIDXのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20009Jonathan Cohen2020biolabs.com20/20 Biolabs, Inc.は、がんや慢性疾患の早期発見・予防を目的とした、AIを活用した検査室ベースの血液検査を開発・商品化している。複数のがんを早期発見する「OneTest for Cancer」（MCED）や炎症バイオマーカーを測定する「OneTest for Longevity」を提供している。また、海外の診断薬新興企業向けのCLIAラボであるClinical Lab Innovation Axcelerator (CLIAx)も運営している。前身は20/20 GeneSystems, Inc.で、2025年3月に20/20 Biolabs, Inc.に社名変更した。同社は2000年に法人化され、メリーランド州ゲイサーズバーグに本拠を置く。もっと見る20/20 Biolabs, Inc. 基礎のまとめ20/20 Biolabs の収益と売上を時価総額と比較するとどうか。AIDX 基礎統計学時価総額US$10.22m収益（TTM）-US$5.09m売上高(TTM)US$1.84m3.4xP/Sレシオ-1.2xPER（株価収益率AIDX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計AIDX 損益計算書（TTM）収益US$1.84m売上原価US$1.34m売上総利益US$501.63kその他の費用US$5.60m収益-US$5.09m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.48グロス・マージン27.19%純利益率-276.19%有利子負債／自己資本比率11.1%AIDX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 11:59終値2026/06/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋20/20 Biolabs, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael OkunewitchMaxim Group
お知らせ • Jun 0220/20 Biolabs, Inc., Annual General Meeting, Aug 18, 202620/20 Biolabs, Inc., Annual General Meeting, Aug 18, 2026.
お知らせ • May 1720/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).
お知らせ • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.
お知らせ • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.
お知らせ • Jun 0220/20 Biolabs, Inc., Annual General Meeting, Aug 18, 202620/20 Biolabs, Inc., Annual General Meeting, Aug 18, 2026.
お知らせ • May 1720/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).
お知らせ • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.
お知らせ • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.
